Bertis Appoints Global Life Sciences Innovation and Sustainability Expert 

Dr. David Berry to Scientific Advisory Board

-   Dr. David Berry, a global authority in innovation and sustainable management, has participated in founding over 30 companies, including Moderna

-   First collaboration with a Korean company as a Scientific Advisory Board member, supporting Bertis’ global expansion

[Image] Dr. David Berry

On February 6th, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it has appointed Dr. David Berry, a world-renowned authority on innovation and sustainable management in the life sciences, as a member of its Scientific Advisory Board (SAB).

Dr. David Berry, who received his MD from Harvard Medical School and PhD in Biological Engineering from the Massachusetts Institute of Technology (MIT), holds over 200 patents in life sciences and other fields. He has co-founded more than 30 companies, including 7 valued at over $1 billion. Notably, Dr. Berry contributed to the establishment of Moderna, a company developing mRNA technology-based vaccines and therapeutics.

As a globally recognized expert in innovation and sustainable management, Dr. Berry currently serves as an Emeritus member of the Leadership Council for the United Nations Sustainable Development Solutions Network (UN SDSN). His achievements have been widely recognized: he was named an Innovator of the Year in 2007 by the MIT Technology Review, a 2014 Young Global Leader by the World Economic Forum, and one of 12 Innovators Helping Reshape Reality by the U.S. State Department.

Dr. Berry's appointment to Bertis' Scientific Advisory Board draws significant attention as it marks his first collaboration with a Korean company. Bertis aims to leverage Dr. Berry's extensive experience and expertise as an innovation leader, inventor, and entrepreneur to formulate its global expansion strategy and establish itself as a leading company in proteomics-based precision medicine technology on the world stage.

Dr. David Berry stated, "Bertis possesses world-class proprietary technology in clinical proteomics and is leading the realization of precision medicine through early disease diagnosis and personalized treatment activation. I look forward to contributing to the global dissemination of Bertis' proteomics-based precision medicine technology and driving innovation in the medical field."

Seung-man Han, CEO of Bertis, emphasized, "Since our founding in 2014, Bertis has built a globally competitive technological framework through continuous challenges and achieved commercialization and technological development in proteomics, including multi-protein biomarker-based blood tests. We expect our collaboration with Dr. Berry to be a significant boost in elevating Bertis to the next level as a globally competitive precision medicine technology company, building on the technological achievements we've accumulated over the past decade."